About Implantica

News & Events

News & Events

News

Implantica receives CE Mark Approval for RefluxStop™, a potential Paradigm shift in the Treatment for Acid reflux

16.08.2018

Implantica, a privately held medtech company, announced today that it has received CE Mark approval for RefluxStop™, a novel approach to treat acid reflux.

The CEO of Implantica MediSwiss AG, Dr. Peter Forsell, states:

“We are pleased to have accomplished this important milestone for all of those suffering from acid reflux. Based on the successful clinical trial results, Implantica’s RefluxStop™ may represent a paradigm shift in the treatment of gastroesophageal reflux disease (GERD) as it more effectively treats acid reflux and does so with reduced side effects since it does not compress the food passageway. Current standard surgical acid reflux treatments are plagued with complications as they compress the food passageway, often resulting in swallowing difficulties and the inability to burp or vomit.”

A literature review and meta-analysis has been performed comparing Nissen fundoplication, the current “gold standard” surgical treatment for acid reflux, with the results from the RefluxStop™ six month clinical investigation for CE mark, which showed that the new method of treating acid reflux works with both better treatment results and fewer side effects.

CE Mark approval has been granted August 8, 2018, on the strength of a multi-center clinical investigation in which the safety and effectiveness of the device in patients was demonstrated. The approval enables the company to market and sell RefluxStop™ in member countries of the European Economic Area and Switzerland.

Acid reflux is a treatment field with approximately 375 million sufferers worldwide. Up to 15% of sufferers develop precancerous changes in their lower esophagus (Barrett’s esophagus) due to acids repeatedly damaging esophageal tissue. It has been shown that drug therapy does not remove the cancer risk, and long-term drug therapy is associated with complications in many patients.

For further information, please contact:

Implantica Management AG

Baarerstrasse 57

6300 Zug

Switzerland

Email:                 [email protected]

Contact person: Nicole Pehrsson, [email protected]

Website:            www.implantica.com

About Implantica

Implantica is a privately held medtech company dedicated to bringing advanced technology into the body. Implantica’s first product, RefluxStop™, will potentially create a paradigm shift in anti-reflux surgery as supported by the successful clinical trial results. Implantica’s wireless energizing platform, developed for eHealth Smart Medical Implants (prototype not yet CE marked), is designed to make previously impracticable medical implants possible with the ability to power remote controlled implants wirelessly through intact skin. In addition, Implantica has developed an eHealth platform (prototype not yet CE marked) to be initially used in combination with upcoming eHealth smart implants and later as a stand-alone eHealth monitoring device, e-InVivo™, which shall collect data from inside the body and transfer the data to external devices or directly to the caregiver. e-InVivo™ is designed to monitor a broad range of health parameters and provide diagnostic information with early detection of diseases as well as control treatment from inside the body.

Implantica nominates Domenico Scala to the Board of Directors

01.03.2018

Implantica MediSwiss AG is pleased to announce the nomination of Mr. Domenico Scala as a member of the Board of Directors. Mr. Scala has extensive experience in leading healthcare companies and was the CEO and President of Nobel Biocare Holding AG from 2007 to 2011 and the CFO of Syngenta International AG from 2003 to 2007. He is currently the Chairman of both Basilea Pharmaceutica AG and Oettinger Davidoff AG.

Mr. Scala’s strong medtech background and long experience as a business leader will be highly valuable for Implantica, pursuing its mission to become the world leader in smart medical implants. The Board is delighted to welcome Mr. Scala on board and is looking forward to our exciting future.

About Implantica

Implantica is an innovative medical device company based on 4 cornerstones:

  • Implantica will soon launch a new device, RefluxStop™, potentially creating a paradigm shift in anti-reflux surgery, supported by clinical trial results.
  • Implantica is in the forefront of the fast expanding eHealth market with its sensor implant e-InVivo™, which collects data from inside the body and transfers the data to external devices, such as a watch or directly to the caregiver.  e-InVivo™  is designed to monitor a multitude of health parameters and provide diagnostic information as well as control treatment from inside the body.
  • Implantica’s wireless energizing platform, developed for the next generation of “Smart Medical Implants”, is designed to make previously unconceivable medical implants possible.
  • Implantica’s extensive patent portfolio facilitates a large product pipeline and creates a “Blue Ocean” market situation allowing for a multitude of medical implants and treatment options.
Implantica nominates Richard Fritschi as Chairman

22.01.2018

Implantica MediSwiss AG is pleased to announce that the Board of Directors has nominated Mr. Richard Fritschi as Chairman. Mr. Fritschi brings extensive experience to the position having served 5 years as CEO of Ypsomed AG and spent over 20 years in executive management positions in the medtech industry with Zimmer Holdings, Centerpulse AG and Sulzer Medica.

The Implantica team values Mr. Fritschi’s strong track record in leading healthcare companies and his significant experience in the medical device field. The Board is delighted that Mr. Fritschi will assume the position of Chairman and is excited to have him join Implantica’s journey.

About Implantica

Implantica is an innovative medical device company based on 4 cornerstones:

  • Implantica will soon launch a new device, RefluxStop™, potentially creating a paradigm shift in anti-reflux surgery, supported by clinical trial results.
  • Implantica is in the forefront of the fast expanding eHealth market with its sensor implant e-InVivo™, which collects data from inside the body and transfers the data to external devices, such as a watch or directly to the caregiver.  e-InVivo™  is designed to monitor a multitude of health parameters and provide diagnostic information as well as control treatment from inside the body.
  • Implantica’s wireless energizing platform, developed for the next generation of “Smart Medical Implants”, is designed to make previously unconceivable medical implants possible.
  • Implantica’s extensive patent portfolio facilitates a large product pipeline and creates a “Blue Ocean” market situation allowing for a multitude of medical implants and treatment options.